Glucagon-like peptide-1 receptor agonists, used for the treatment of type 2 diabetes, have been reported to exert two beneficial effects on pancreatic islet hormone secretion: the promotion of insulin secretion and the suppression of glucagon secretion [41]. This evidence concerns the gene INS and type 2 diabetes mellitus.